SoT,
I rated up that post, great post!
Not at all, in fact that is what I think they will inevitably need to do.
As Enumerate suggested, and I agree with, that PYC or actually their partners will need to optimize hits (potentially requiring a significant amount of time), and they will want to do this (or confirm they can do this) prior to taking a license. IMO I don't believe anyone will try to develop a selected phylomer as is, knowing that BigPharma always takes the path that they can optimize a candidate and make it better.
I said in a post last year that PYC should be also attempting to focus on providing services to optimize their hits, because they could get R&D funding from that, and the more tied to a partner you are the better. Their model of providing just hits to a partner and then waiting while the partner evaluates them is a very very difficult model IMO.
Again, great post SoT, I think you right on.
- Forums
- ASX - By Stock
- PYC
- Ann: Core patent granted in Australia
Ann: Core patent granted in Australia , page-33
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PYC (ASX) to my watchlist
(20min delay)
|
|||||
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $466.6M |
Open | High | Low | Value | Volume |
10.0¢ | 10.5¢ | 10.0¢ | $86.50K | 841.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 634012 | 10.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.5¢ | 256545 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 634012 | 0.100 |
2 | 711139 | 0.099 |
3 | 160000 | 0.098 |
2 | 105176 | 0.097 |
1 | 100000 | 0.096 |
Price($) | Vol. | No. |
---|---|---|
0.105 | 256545 | 9 |
0.110 | 963441 | 7 |
0.115 | 1308674 | 7 |
0.120 | 570289 | 4 |
0.125 | 366111 | 3 |
Last trade - 13.22pm 09/08/2024 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |